From Drug Benefit News - Pharmaceutical manufacturers, covered entities and other stakeholders in the 340B Drug Pricing Program are once again sweating it out as an expected “mega-guidance” spends its third month at the Office of Management and Budget (OMB). Industry insiders say the pending guidance could, among other things, finally place some limits on the wildly expanding contract pharmacy arrangements that may lead to duplicate discounts being paid by manufacturers to 340B entities and commercial and/or Medicaid plans. Read more
From Specialty Pharmacy News - If 10% of Californians who have hepatitis C are treated with newer, more effective yet costly specialty drugs, projected costs over the next 12 months would be $4.77 billion, with $2.05 billion of that spent on the state-funded population. That’s one of the findings of a study conducted by The Taylor Feldman Group for the California Association of Health Plans that was released last month. Read more
From Specialty Pharmacy News - In the latest in a long list of dustups over new hepatitis C drugs, two public health advocacy groups are suing the FDA and HHS in an effort to force the FDA to release raw clinical trial data for Gilead Sciences Inc.’s Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), which were given priority review and breakthrough-therapy designation. The organizations are seeking the data because information “suggest[s] that the drugs have been widely… Read more
Check out all of the benefits, sample issues & more!